- 著者
- Hikichi Takafusa Matoba Ryo Ikeda Takashi Watanabe Akira Yamamoto Takuya Yoshitake Satoko Tamura-Nakano Miwa Kimura Takayuki Kamon Masayoshi Shimura Mari Kawakami Koichi Okuda Akihiko Okochi Hitoshi Inoue Takafumi Suzuki Atsushi Masui Shinji
- 出版者
- National Academy of Sciences
- 雑誌
- Proceedings of the National Academy of Sciences of the United States of America (ISSN:10916490)
- 巻号頁・発行日
- 2013-04-02
- 被引用文献数
- 31
初期化を阻害する転写因子が分化を促進する. 京都大学プレスリリース. 2013-04-02.
- 著者
- Suzuki Atsushi Sekiguchi Sahoko Asano Shogo ITOH Mitsuyasu
- 出版者
- The Japanese Pharmacological Society
- 雑誌
- Journal of pharmacological sciences (ISSN:13478613)
- 巻号頁・発行日
- vol.106, no.4, pp.530-535, 2008-04-20
- 参考文献数
- 40
- 被引用文献数
- 3 21
The prevention of osteoporotic fracture is an essential socioeconomical priority, especially in the developed countries including Japan. Estrogen, selective estrogen-receptor modulators (SERMs), and bisphosphonate are potent inhibitors of bone resorption; and they have clinical relevance to reduce osteoporotic fractures in postmenopausal women. However, we can prevent at most 50% of vertebral fractures with these agents. For the better compliance of aminobisphosphonate, the use of a daily bisphosphonate regimen is moving to a weekly or monthly bisphosphonate regimen. Both cathepsin K inhibitors and modulators of the RANK-RANKL system, which can reduce bone resorption, are the candidates for the future treatment of osteoporosis. As well as bone resorption, we need to increase bone formation to prevent osteoporotic fractures, particularly in elderly patients with low bone turnover. In the U.S., Europe, and Australia, they have already started intermittent parathyroid hormone injection and/or oral strontium ranelate to stimulate bone formation. We still need to discover new agents to reduce osteoporotic fractures for the better quality of life without fractures.<br>